Six months ago Synthomer plc (LSE:SYNT) was fighting to refinance a Debt pile that dwarfed its market value. Today the FTSE SmallCap speciality chemicals group is telling the market that full-year 2026 Earnings will come in slightly ahead of expectations. That reversal, delivered on 4 August 2026 alongside interim results showing EBITDA up 13% at constant currency, has made the polymer maker one of the more unusual recovery stories on the London Stock Exchange this year.

The question now is whether the momentum is durable. Management concedes that roughly £6m of first-half EBITDA came from Iran-conflict disruption and will not recur, while net debt of £671.3m still sits at 4.9 times covenant EBITDA. Genuine self-help progress is being weighed against a Balance Sheet with little Margin for error.

Interim results and guidance upgrade: EBITDA up 13% as margins recover

On 4 August 2026 Synthomer reported results for the six months to 30 June 2026. Continuing Revenue rose to £954.3m from £894.4m a year earlier, up 5.1% at constant currency, and EBITDA climbed to £96.7m from £83.1m, a 13.4% constant-currency increase. The EBITDA margin widened by 80 basis points to 10.1%. Underlying operating profit increased to £48.6m (H1 2025: £34.3m) and Underlying Profit before tax rose to £12.7m from £1.3m, although the statutory loss before tax was still £25.5m, narrowed from £36.9m, after finance costs of £35.4m and £7.0m of restructuring charges.

The board said full-year 2026 performance is now expected to be slightly ahead of market expectations, provided the second half delivers a broadly similar contribution from growth initiatives and cost savings. Chief executive Michael Willome attributed most of the progress to "our sustained efforts to become a more speciality-focused company and our consistent work to 'control the controllables'", adding that the market "will continue to require us to be fast and bold".

The upgrade carries a caveat. Synthomer estimates that around £6m of second-quarter EBITDA reflected Iran-conflict effects, including customer pre-buying and Supply disruption at Asian competitors, and does not forecast that to repeat. It expects the £8m improvement from strategic growth and self-help to be sustained, while second-quarter pricing to pass through higher raw material and energy costs is expected to unwind in the second half.

What Synthomer does

Synthomer is a British-headquartered producer of speciality polymers, mainly water-based dispersions and resins, sold to around 6,000 customers across Europe, the Middle East and Africa, Asia Pacific and the Americas, through three market-facing divisions.

Coatings and Construction Solutions, the largest with first-half revenue of £400.5m, supplies binders for paints, construction chemicals and energy-sector additives. Adhesive Solutions (£304.2m) makes resins and polymers for tapes, labels and packaging. Health and Protection and Performance Materials (£249.6m, continuing basis) produces nitrile latex for medical gloves alongside polymers for paper, carpet and foam.

The group has been shrinking to grow. It has cut its Manufacturing footprint to 29 sites from 43 in 2022, targeting 25 or fewer, and has agreed four non-core divestments since 2022, most recently the loss-making Acrylate Monomers plant at Sokolov in the Czech Republic, sold to Mutares on 19 June 2026 for up to €12m of deferred cash, completing by the end of the third quarter. Three further divestment processes are under way.

Financial position: profit recovery meets heavy debt

The full-year 2025 results, published on 30 April 2026, showed how far the Business had fallen. Group revenue dropped to £1,739.2m from £1,933.1m in 2024, EBITDA edged down to £136.5m from £143.1m and the loss before tax widened to £114.1m from £87.6m, including £22.5m of impairments; basic loss per share was 96.0p. Free Cash Flow did turn positive at £56.6m, and net debt fell to £575.0m, with covenant Leverage of 4.7 times.

The first half of 2026 reversed some of that cash progress. Free cash flow was an outflow of £80.8m (H1 2025: £30.3m outflow) as Working Capital absorbed £105.0m, reflecting higher raw material costs, seasonal inventory build and the unwinding of a £50m receivables arrangement with largest Shareholder KLK. Net debt rose to £671.3m, and factored receivables stood at £149.8m net.

The April 2026 refinancing extended a €300m revolving Credit Facility and €288m and $230m UK Export Finance facilities to February 2029, alongside €350m of 7.375% senior notes due May 2029. Leverage covenants step down from 6.25 times at the end of 2026 to 4.25 times in 2028, with intra-year testing from 30 September 2026. Committed Liquidity was £268m at the half-year. Management guides to Capital Expenditure of around £70m, positive full-year free cash flow before receivables finance movements and year-end covenant leverage of 4.0 to 4.35 times, before further disposals. No Dividend is being paid.

What could drive the stock next

Shares traded at around 104p to 107p in early September, valuing Synthomer at roughly £171m against a 52-week range of 16.70p in March and 123.60p in June, according to lse.co.uk. Completion of the Acrylate Monomers sale removes a business that lost €10m of adjusted EBITDA in 2025, and any of the three remaining divestment processes would directly reduce debt, the metric the market is most focused on.

The autumn trading statement, which in 2025 came on 23 October, will show whether second-half trading is holding up without the Iran-related boost. Cost programmes are another lever: £13m of run-rate benefits were delivered in the first half, and the Adhesive Solutions programme has reached £40m of a targeted £43m. A permanent chief financial officer is also awaited, following Lily Liu's departure to Umicore and Iain Torrens's interim arrival in May.

Risks investors should watch

Leverage is the dominant risk. Net debt of £671.3m is close to four times the market capitalisation, and the refinancing came with a 1.25% exit fee and Options for UKEF lenders to take shares at 37.5p. Covenant headroom depends on EBITDA continuing to rise while working capital normalises; a Demand downturn in construction, coatings or gloves would test the 6.25 times year-end limit.

Cash conversion has been volatile, and the group relies on receivables factoring, which flatters headline net debt. Roughly £6m of first-half EBITDA is acknowledged as non-recurring, raw material and energy prices remain sensitive to Middle East events, and the statutory picture still shows losses. KLK's position as largest shareholder and former counterparty on the £50m receivables arrangement means its intentions matter to the share register.

Outlook

Synthomer has moved from refinancing survival to guidance upgrade in six months, and the operating metrics suggest the speciality strategy is gaining traction. Whether that translates into lasting value depends on the second half delivering the cash flow management has promised and on disposals chipping away at debt. The 30 September covenant test, the Sokolov completion and the October trading update are the next checkpoints for a story that still has plenty left to prove.